PENNSYLVANIA, March 14 - statins, one of the leading lipid-lowering therapies, actually

achieve healthy levels of LDL-C; and

WHEREAS, The total direct and indirect cost of ASCVD in the

United States was $555 billion in 2016 and is projected to climb

to $1.1 trillion by 2035 according to the American Heart

Association; and

WHEREAS, In Pennsylvania, 931,400 adults have been told by a

health professional that they had angina, a stroke, a heart

attack or coronary heart disease, which are some of the

manifestations of ASCVD; and

WHEREAS, In Pennsylvania, 17,653 people had ASCVD as an

underlying cause of death; and

WHEREAS, In Pennsylvania, 456,300 adults reported

experiencing a heart attack in their lifetime, and 382,400

adults reported experiencing a stroke in their lifetime; and

WHEREAS, Pennsylvania spends an estimated $5.5 billion on

direct medical expenses for ASCVD care each year; therefore be

it

RESOLVED, That the Senate of the Commonwealth of Pennsylvania

designate the month of February 2023 as "Atherosclerotic

Cardiovascular Disease Month" in Pennsylvania; and be it further

RESOLVED, That the Senate of the Commonwealth of Pennsylvania

urge Commonwealth agencies to expand comprehensive

cardiovascular screening programs to allow for earlier

identification of patients at risk of cardiovascular events; and

be it further

RESOLVED, That the Senate of the Commonwealth of Pennsylvania

urge Commonwealth agencies to explore ways to collaborate with

Federal public and private national agencies and organizations

to establish or expand comprehensive cardiovascular screening

20230SR0056PN0471 - 2 -

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30